Key Highlights
- Shares of Artelo Biosciences (ARTL) climbed more than 40% during pre-market hours on March 18, 2026
- The rally followed news of a fully-funded clinical trial partnership with Belfast Health and Social Care Trust
- The trial will evaluate ART27.13, a peripherally selective synthetic cannabinoid, in glaucoma and ocular hypertension patients
- Financial backing comes from Glaucoma UK and the HSC R&D Division, with initial patient recruitment slated for Q2 2026
- This announcement arrives weeks after a 1-for-3 reverse stock split implemented on March 10, 2026
Shares of Artelo Biosciences (ARTL) skyrocketed over 40% in Wednesday’s pre-market session following the company’s disclosure of a fully-funded clinical research partnership to evaluate its synthetic cannabinoid candidate ART27.13 in glaucoma treatment.
Artelo Biosciences, Inc., ARTL
The investigator-led clinical trial was established through a collaboration agreement with Belfast Health and Social Care Trust (BHSCT). Financial support will be provided by Glaucoma UK alongside the HSC R&D Division.
Designed as a pilot randomized cross-over study, the trial will assess ART27.13’s ability to reduce intraocular pressure (IOP) in individuals diagnosed with glaucoma or ocular hypertension.
ART27.13 functions as a peripherally selective synthetic cannabinoid receptor agonist. This mechanism allows it to engage cannabinoid receptors located in peripheral body tissues—such as those in the eye—while avoiding interaction with the central nervous system.
Current glaucoma therapies predominantly rely on topical eye drop formulations, which often face challenges with patient compliance and sustained efficacy. According to Artelo, ART27.13’s unique design could circumvent the psychoactive adverse effects that have historically hindered cannabinoid-based ocular medications.
Regulatory clearance for the study protocol has already been obtained from both an ethics review board and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The company anticipates enrolling the first participant during Q2 2026.
Professor Augusto Azuara-Blanco will serve as the trial’s principal investigator. He holds the position of clinical professor of ophthalmology at Queen’s University Belfast and is widely regarded as an authority in glaucoma research.
Glaucoma impacts over 80 million individuals globally and ranks among the primary causes of permanent vision loss. Elevated IOP remains the principal modifiable risk factor in disease advancement.
Capital-Conscious Development Approach
CEO Greg Gorgas characterized the partnership as a component of the company’s broader resource-efficient development framework. The arrangement allows external sponsors to manage this study while Artelo maintains internal resources focused on ART27.13’s core indication—cancer-associated anorexia.
“This collaboration exemplifies our capital-efficient development strategy,” Gorgas said in the announcement. “Each study contributes to a growing body of evidence that could enhance the value of ART27.13.”
Under the terms of the collaboration, Artelo will provide ART27.13 capsules as the Investigational Medicinal Product for the research. All other financial responsibilities rest with the study’s external funding sources.
Financial Performance Background
The pre-market rally unfolds amid a difficult financial landscape for the company. Artelo disclosed a net loss of $12.9 million for the fiscal year concluded December 31, 2025, representing an increase from the $9.8 million loss recorded in the prior year.
Cash reserves and investments totaled only $0.6 million at year-end. InvestingPro’s Financial Health Score categorizes the company as “WEAK.”
The company executed a 1-for-3 reverse stock split on March 10, 2026. The consolidation reduced outstanding common shares from roughly 2.1 million to 708,323 post-adjustment.
Before Wednesday’s movement, ARTL shares had fallen 67% during the preceding six-month period. The stock was quoted at $4.85 with a market capitalization of approximately $3.47 million ahead of the pre-market surge.
The glaucoma research initiative marks Artelo’s inaugural venture into ophthalmology and its first externally-financed clinical collaboration.
